ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0616

Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes

Liam O'Neil1, XIAOBO MENG1, Caitin McFadyen1, Marvin Fritzler2 and Hani El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

Meeting: ACR Convergence 2022

Keywords: Anti-CCP, Biomarkers, prevention, proteomics, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin the loss of immune tolerance and the progression toward pathogenic autoimmunity remain unclear. We sought to identify changes in circulating cytokine/chemokine networks that are associated with the presence and persistence of ACPA, and with the progression towards inflammatory arthritis in an at-risk cohort of first-degree relatives (FDR) of RA patients.

Methods: We studied baseline serum samples from a cohort of at-risk FDR (n = 147) and quantified serum cytokines/chemokines using a 48-plex platform. Longitudinal outcomes were defined on the basis of ACPA status and progression into inflammatory arthritis (IA). K-means clustering, differential expression, and principal components analysis were used to identify group level differences. A co-expression module analysis was used to identify enriched networks. ACPA Fab glycosylation was calculated as a % of total IgG. A Random Forest (RF) machine learning approach was used to classify ACPA positive individuals. Network analysis was used to understand underlying biological processes based on protein expression.

Results: Baseline demographics were balanced between ACPA positive (n = 48) and ACPA negative FDR (n = 99). We defined 6 proteomic clusters, with enrichment of ACPA positive samples in cluster 6 (p < 0.0001). As such, 23 of 24 differentially expressed proteins in ACPA positive samples were upregulated, including CCL11, IFNg and IL1b. A co-expression network was identified, and protein network member expression (n = 23 members) was higher in baseline ACPA positive sera (p = 0.0005) and in individuals who progressed into IA (p = 0.0003), but not those who subsequently became seronegative for ACPA during the observation period. The co-expression network correlated with ACPA Fab glycosylation % (R = 0.49, p = 0.049), a known marker of future disease progression. RF achieved an area under the curve of 0.767 to classify ACPA positive sera in a test dataset. Network analysis revealed upregulation of JAK-STAT signalling in those at highest risk to develop future IA, along with several drugs that may modulate this pathway.

Conclusion: A serum proteomic analysis focused on cytokine/chemokine networks provides a rich dataset with which to better understand biological processes in pre-clinical RA. This approach allowed us to identify key pathways that were associated with ACPA seropositivity, and progression towards IA onset. A combination of ACPA and the identified serum biomarkers, may increase the precision with which to predict future RA in at-risk individuals.

Supporting image 1

A serum protein module score measured in baseline serum samples is associated with progression into inflammatory arthritis in FDR of RA patients. The score was not significantly different between ACPA FDR who underwent seroconversion and ACPA negative FDR.

Supporting image 2

A serum protein module score correlated with ACPA IgG Fab glycosylation.


Disclosures: L. O'Neil, None; X. MENG, None; C. McFadyen, None; M. Fritzler, Mitogen Diagnostics Corporation; H. El-Gabalawy, None.

To cite this abstract in AMA style:

O'Neil L, MENG X, McFadyen C, Fritzler M, El-Gabalawy H. Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/serum-proteomic-networks-associate-with-pre-clinical-rheumatoid-arthritis-autoantibodies-and-longitudinal-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-proteomic-networks-associate-with-pre-clinical-rheumatoid-arthritis-autoantibodies-and-longitudinal-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology